Question

A patient is being evaluated for thyroidectomy for an indeterminate thyroid nodule. Which of the following is considered a contraindication for surgery?

• A. History of prior neck radiation
• B. Negative molecular profile on ThyroSeq v3
• C. Uncorrectable coagulopathy
• D. Severe uncontrolled cardiopulmonary disease

Hint:

Molecular testing (ThyroSeq, Afirma) is specifically indicated for Indeterminate nodules (Bethesda III/IV) to prevent unnecessary diagnostic lobectomies.
Negative Molecular Test = Treat as Benign (Observe).

Answer 1

The Correct Option is B

Concept:
The clinical scenario revolves around the modern decision-making algorithm for a patient with a cytologically "indeterminate" thyroid nodule (typically Bethesda Category III or IV).
The clinician must identify which specific test result serves as an algorithmic indication to avoid (or contraindicate) diagnostic surgical resection.
Explanation:
• When a Fine Needle Aspiration Cytology (FNAC) yields an indeterminate result, the actual risk of malignancy remains uncertain, generally hovering between 10% and 30%.

• Historically, all these patients underwent a diagnostic thyroid lobectomy simply to rule out cancer, resulting in many unnecessary surgeries for benign nodules.

• Modern ATA (American Thyroid Association) guidelines highly recommend utilizing molecular testing panels (such as ThyroSeq v3 or Afirma) to further risk-stratify these specific indeterminate nodules.

• These molecular panels test for hundreds of genetic mutations and RNA alterations known to be associated with thyroid malignancies.

• If the molecular profile returns negative (a benign result), the test has an exceptionally high negative predictive value.

• A negative ThyroSeq v3 result reduces the probability of malignancy to less than 5%, rendering it statistically equivalent to a purely benign FNAC result (Bethesda II).

• Because the nodule is now scientifically proven to be highly likely benign, subjecting the patient to the inherent risks of a thyroidectomy (recurrent laryngeal nerve injury, hypoparathyroidism, general anesthesia) is no longer clinically justified.

• Therefore, in the context of thyroid nodule management pathways, a negative molecular profile acts as a specific contraindication to diagnostic surgery; the patient should instead undergo active ultrasound surveillance.

• While Options C and D are absolute systemic medical contraindications to any elective surgery, Option B is the specific, answer intended for this endocrinology question.
Final Answer:
A negative molecular profile confirms a very low risk of malignancy, thereby contraindicating diagnostic surgery in favor of active surveillance.